PremiumCompany AnnouncementsAvacta Group Completes Transition to Pure-Play Therapeutics with Sale of Coris Bioconcept Avacta Group Settles Convertible Bond Installment Amidst Recent Equity Financing Avacta Group Secures £3.25 Million in Strategic Equity Fundraise PremiumCompany AnnouncementsAvacta Reports Promising Results in Salivary Gland Cancer Trial Avacta Group’s Earnings Call: Oncology Focus and Financial Challenges Avacta Group Announces 2024 Annual Report and Revised AGM Date PremiumCompany AnnouncementsAvacta Group PLC to Announce FY24 Results and Host Investor Presentation Avacta Group Announces Investor Webinar on Latest Cancer Therapy Developments Avacta Group Seeks AIM Block Listing for 6.5 Million Shares